Home › Compare › CYRNQ vs ABBV
CYRNQ yields 2000000.00% · ABBV yields 3.06%● Live data
📍 CYRNQ pulled ahead of the other in Year 1
Combined, CYRNQ + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CYRNQ + ABBV for your $10,000?
Cyren Ltd., together with its subsidiaries, provides cloud delivered Software-as-a-Service (SaaS) cybersecurity solutions that protect businesses, their employees, and customers against threats from email, files, and the web. It provides Cyren threat detection services, which include email security engine that offers anti-spam inbound and outbound, IP reputation, and virus outbreak detection services; malware detection engine that is used to protect email applications; Web security engine, which is used by customers to provide URL classification for web browser filtering and safe search capabilities; and threat analysis services to detect advanced cyber threats. The company also provides Cyren threat intelligence data products, which include real-time phishing intelligence, malware file intelligence, IP reputation intelligence, malware URL intelligence, and Zombie host intelligence for threat detection, threat hunting, and incident response. In addition, it offers Cyren enterprise email security products, including Cyren Email Security, a cloud-based secure email gateway; and Cyren Inbox Security, an anti-phishing and remediation product for Microsoft 365. The company sells its products through direct and indirect channels, including distributors, value added resellers, and managed service providers to enterprise customers and original equipment manufacturers. It has operations in the United States, Germany, other European countries, the Asia Pacific, Israel, and internationally. The company was formerly known as Commtouch Software Ltd. and changed its name to Cyren Ltd. in January 2014. Cyren Ltd. was incorporated in 1991 and is based in Herzliya, Israel.
Full CYRNQ Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.